September 2017 Issue of MMM
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a ...
At Work With
When you've figured out the difference, people will walk through fire for you, a mentor once told her.
Read the September 2017 issue in its entirety, including how marketing can save clinical trials.
They are using social media campaigns, apprentice programs, and hands-on internships to recruit young, innovative talent right out of school.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
Alone among the best-known social platforms, Snapchat has failed to generate much enthusiasm from pharma. Here's why — and here's why that may change.
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
David Musselman and Lynn Gerber are now leading sales for the company's primary care and specialty products.
The CEO of Huntsworth's biggest and fastest-growing unit Huntsworth Health, which includes Nitrogen and Tonic Life, has departed after eight years.
O'Connor Vos has served as CEO of the WPP Health & Wellness agency since 1994.
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
What's holding back value-based pricing deals from moving beyond the pilot phase?
As the influence of patient communities and advocacy groups grows, how can marketers work these organizations to achieve brand objectives?
That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.
More than other patient groups, they want a deeper, ongoing relationship with caregivers.
If scientific storytelling alone can impact health outcomes, then how can we apply that knowledge in practice?
While multiple sclerosis can take a marked toll on patients and families, the message of optimism in these ads has never been more profound.
The coming digital revolution will change a lot of things, but I guarantee this: It won't replace the importance of the patient-physician relationship.